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Optimized HBsAg titer monitoring improves interferon therapy
in patients with chronic hepatitis delta
To the Editor:
Hepatitis delta virus (HDV) is a defective virus requiring the
simultaneous presence of hepatitis B virus (HBV) to fully express
its pathogenicity; thus, HDV infection always occurs in the
presence of HBV. Active HDV co- or superinfection with HDV is
conﬁrmed by the presence of detectable HDV RNA, and immuno-
histochemical staining for HDV antigen or IgM anti-HDV.
Interferon alpha (conventional or pegylated) is the only drug
effective on HDV replication [1–5]. However, the optimal dura-
tion of interferon (IFN) therapy is not well deﬁned [6,7]. The
efﬁcacy of IFN therapy can be assessed during treatment (after
3–6 months) by measuring HDV RNA levels, but HDV RNA assays
are not standardized and not widely available [7]. Treatment with
pegylated interferon alfa-2a (PegIFN-a-2a) for 48 weeks, which is
considered as the treatment of choice for HDV infection, with or
without adefovir, resulted in sustained HDV RNA clearance in
about one quarter of patients [8]. A sustained off-treatment viro-
logical response with HDV RNA-negative is accompanied by
improved histology, while some patients lose the HBV surface
antigen (HBsAg) [6,7].
The aim of our study was ﬁrst to prospectively monitor HBsAg
titers during interferon therapy for the treatment of chronic HDV
and, second, to adapt the duration of the therapy based on the
titer.
We analyzed HBsAg levels of four patients who received
PegIFN-a-2a as a time-individualized therapy according to the
evolution of HBsAg titer. All patients were male, HBe Ag-negative,
and with an age of 43–46 years. Metavir score was F4 for one
patient and F3 for the others. Pretherapeutic HBsAg levels were
7900, 4200, 3500, and 1320 IU/ml (Fig. 1).
We prospectively assessed the HBsAg titers using the Quanti-
tative Architect Abbott Method (Abbott France, Rungis, France)
every three months in these four patients who received PegIFN-
a-2a at 180 lg per week. The treatment was stopped when
HBsAg levels reached negative values (<0.5 IU/ml). During inter-
feron treatment, HBsAg titers decreased in all patients and
reached a negative value (<0.5 IU/ml) after seven months, two
years, three years, and four years of therapy. This negative HBsAg
value was stable (normal ALT and loss of HBsAg) in all patients
12 months after the end of therapy.
Few data are reported on extended treatment for chronic
HDV. Yurdaydin et al. treated patients during two years, without
increased sustained response rates during one year of treatment
[9]. In their study, the treatment duration was ﬁxed and not
based on HBsAg monitoring of patients. In our study, the decline
of HBsAg titers varied among the patients. Loss of HBsAg
occurred after seven to 48 months, and only close monitoring
of HBsAg revealed the end of therapy. HBsAg titer decline
constitutes a useful tool to predict HBsAg loss and the best
duration of interferon treatment in chronic HDV. Even with a lim-
ited number of patients, this study demonstrates, for the ﬁrst
time, that adapting interferon treatment duration through HBsAg
titer monitoring provides a loss of HBsAg and the cure of chronic
HDV.
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Fig. 1. HBs antigen monitoring during interferon treatment for chronic
hepatitis delta in four patients.
Journal of Hepatology 2013 vol. 58 j 1258–1266
Letters to the Editor
Denis Ouzan⇑
Institut Arnault-Tzanck, Saint-Laurent du Var, France⇑Corresponding author.
E-mail address: denis.ouzan@wanadoo.fr
Guillaume Pénaranda
Laboratoire Alphabio, Marseille, France
Hélène Joly
Institut Arnault-Tzanck, Saint-Laurent du Var, France
Philippe Halfon
Laboratoire Alphabio, Marseille, France
Hôpital Ambroise Paré, Marseille, France
Usefulness of Lead-In phase in determining risk/beneﬁt
of telaprevir treatment in patients with HCV cirrhosis
To the Editor:
We read with interest the paper published by Dr. Foster and co-
authors [1]. As clearly stated in the manuscript, irrespective of
the previous deﬁnition of response, the overall SVR rates at week
4, after Lead-In phase (LI), were 33% in those with <1 log decline
and 82% in the subset with >1 log decline, respectively. Multiple
logistic regression analysis conﬁrmed that LI is a strong indepen-
dent predictor of SVR (OR 5.1, 95% CI 2.6–10.1). This ﬁnding
enhances the concept that the degree of interferon sensitivity
plays a major role in modulating the efﬁcacy of ﬁrst generation
protease inhibitors. Despite this result, the data provided by this
study did not fully assess the potential usefulness of LI phase in
the context of triple therapy with telaprevir (TVR), because they
lack to further detail the effect of LI according to the ﬁbrosis
stage. Along this line, it also should be taken into account that
patients with advanced ﬁbrosis/cirrhosis represent, in real life,
the majority of those to deal with for re-treatment, and missing
or unreliable data on virologic on-therapy response during previ-
ous treatment is common.
In previous subanalyses carried out in the Realize study [2,3],
the overall SVR rates in null and partial responders with cirrhosis
(Metavir F4) were 14% and 34% (pooled TVR arms), respectively.
More recently, the same group of investigators also reported that
the proportion of patients with cirrhosis increased from relapsers
to null responders, whatever the response after 4 weeks of ther-
apy [5]. Considering this result, a further decrease of response
rate across the prior failure categories, according to the presence
of a more severe liver damage, should be suspected. Regrettably,
in these reports, SVR rates according to ﬁbrosis stages and LI were
not illustrated. In the same way, of main interest, the present
paper missed to provide the rate of SVR in F4 patients who had
less than 1 log decline after LI (overall and according to their prior
deﬁnition of response). This information, by contrast, was
recently stated for boceprevir (BOC, SPRINT 2 and RESPOND 2
combined) [4].
To date, while waiting for more effective molecules that will
eliminate the need of IFN, a detailed analysis of week 4 response
by severity of liver damage represents a no longer deferrable
unmet clinical need. Using this information, both Scientiﬁc Com-
munity and Clinicians worldwide could better determine the util-
ity of LI in assessing the risk/beneﬁt of treatment in cirrhotic
patients with either BOC or TVR triple combination therapy [6,7].
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